Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial

By P. Gionchetti, F. Rizzello, U. Helwig, A. Venturi, K. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli, M. Campieri. Gastroenterology, 2000

1,175 citations recorded by the source corpus.

Subfields: Food Science, Gastroenterology, Genetics

View Paper: https://www.semanticscholar.org/paper/367c2c7f10145eee325e50272948f857bc2114fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

1. G. Schatzmayr
2. R. Sartor
3. M. Manai
4. Herbert Tilg
5. T. Kanai
6. K. Matsuoka

In Genetics

1. R. Sartor
2. S. Bischoff
3. Herbert Tilg
4. T. Kanai
5. K. Matsuoka
6. J. Turner

Citations in the corpus

• Assessment of potential probiotic properties and multiple bacteriocin encoding-genes of the technological performing strain Enterococcus faecium MMRA (2014, background): “…a higher resistance to the intestinal flow of digesta, an optimal functionality and expression of health promoting physiological functions and may also contribute to competitive exclusion (Collado, Gueimonde, Hernandez, Sanz, & Salminen, 2005; Gionchetti et al., 2000; Gueimonde & Salminen, 2006).”
• Probiotics and phytogenics for poultry: myth or reality? (2010, background): “Some probiotic preparations have been examined for their effectiveness in the prevention and treatment of antibiotic-associated diarrhea and inflammatory bowel disease [16, 17].”
• Intestinal permeability – a new target for disease prevention and therapy (2014, background): “The next important finding was that the probiotic mixture VSL#3 reduces and protects against pouchitis in patients with UC [185,186].”
• Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome (2019, background): “Prebiotics are indigestible food ingredients, usually carbohydrates, which can promote the growth and activity of selected beneficial gut microbes and provide benefits to the host’s well-being by the amelioration of enteric dysfunction [113].”
• Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis (2003, background): “32 Some potential mechanisms for the beneficial effect of VSL # 3 in inflammatory bowel disease and pouchitis have been elucidated.”
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (2010, background): “353 ) and in the prevention of pouchitis relapse (”
• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “There is evidence for the effectiveness of VSL#3 in preventing pouchitis”
• Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body (2021, background): “The conclusion was that VSL#3 is effective in pouchitis prevention (149).”
• The gut microbiota and host health: a new clinical frontier (2015, neutral): “81 A meta-analysis has shown that VSL”